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Abstract: Telomere dysfunction has been strongly implicated in the initiation of genomic instability
and is suspected to be an early event in the carcinogenesis of human solid tumors. Recent findings
have established the presence of telomere fusions in human breast and prostate malignancies; however,
the onset of this genomic instability mechanism during progression of other solid cancers is not well
understood. Herein, we explored telomere dynamics in patient-derived epithelial ovarian cancers
(OC), a malignancy characterized by multiple distinct subtypes, extensive molecular heterogeneity,
and widespread genomic instability. We discovered a high frequency of telomere fusions in ovarian
tumor tissues; however, limited telomere fusions were detected in normal adjacent tissues or benign
ovarian samples. In addition, we found relatively high levels of both telomerase activity and hTERT
expression, along with anaphase bridges in tumor tissues, which were notably absent in adjacent
normal ovarian tissues and benign lesions. These results suggest that telomere dysfunction may
occur early in ovarian carcinogenesis and, importantly, that it may play a critical role in the initiation
and progression of the disease. Recognizing telomere dysfunction as a pervasive feature of this
heterogeneous malignancy may facilitate the future development of novel diagnostic tools and
improved methods of disease monitoring and treatment.
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1. Introduction
The telomere, terminal chromosomal tandem DNA repeats and associated proteins, prevents
the cellular DNA repair machinery from recognizing chromosome ends as double strand breaks [1].
Telomerase is a special DNA polymerase with an integral RNA moiety that acts as a template for the
synthesis of telomeric DNA [2]. Human mitotic somatic cells generally do not contain sufficient levels of
telomerase to maintain telomere length, which causes telomere shortening with each cell cycle due to the
“end replication problem” presented by conventional cellular DNA polymerases. Gradually, telomere
function is lost with continual erosion of telomeric DNA, which can lead to unprotected chromosome
ends and subsequent chromosome end-to-end fusions (telomere fusions) [3,4]. Cells with potentially
only one or a few critically shortened telomeres are likely eliminated via senescence and/or cell death
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pathways [5–7]. However, a very rare cell (or cells) may bypass these cellular elimination pathways
resulting in telomere dysfunction-induced genomic instability via breakage-fusion-bridge cycles.
Additionally, continual modes of telomere dysfunction may induce genomic instability throughout
tumorigenesis [8]. Almost two decades ago, it was discovered that high levels of human telomerase
activity are present in the majority of human solid tumor cells. However, the exact mechanism that
leads to high levels of telomerase activity in human tumor cells remains largely unknown [2].
Although the general role of telomere dysfunction in the development of human cancer has been
widely acknowledged, direct evidence of damaged telomeres in human cancer has begun to appear [9].
Shortened telomeres and telomere fusions have been detected in blood samples from patients with
early stage chronic lymphocytic leukemia, and telomere shortening and fusion events were found to
increase as the disease advanced [10]. Research has also shown the presence of telomere fusions in
early human breast carcinoma (DCIS, ductal carcinoma in situ) and invasive ductal carcinoma, while
fusions in normal tissues were notably absent [11]. Additionally, benign prostatic hyperplasia (BPH),
high-grade prostatic intraepithelial neoplasia (PIN), and prostate cancer (PCa) prostate lesions all
contain similarly high frequencies of telomere fusions, while tumor-adjacent, histologically normal
prostate tissue generally did not contain telomere fusions [12]. Taken together, this evidence suggests
that telomere fusions may occur early in tumorigenesis and may function as a driving force in cancer
development, genetic heterogeneity, and progression.
Ovarian cancer is the most common cause of death from gynecologic malignancies with 10-year
survival rates less than 30% [13]. Due to diagnosis at late, advanced stages, these cancers are exceedingly
challenging to treat and therefore identification of early molecular changes associated with development
of ovarian cancers has been an area of intense interest. Characterization efforts, however, have only
rendered the disease more frustratingly complex, as detailed examinations of histological profiles and
genetic aberrations have revealed a wide array of critical gene mutations, copy number alterations,
variations in gene expression, and epigenetic modifications that vary dramatically between ovarian
cancer subtypes and even divide some subtypes into further delineated categories [14,15]. The vast
degree of heterogeneity found in ovarian cancer increases the necessity of finding common, unifying
features of the disease that can be used to develop new methods of early detection. Our hypothesis is
that human ovarian tumor tissue contains significant amounts of telomere fusions, as found in the
other human carcinomas (breast and prostate) on which we have previously reported [11,12].
The high-grade serous cancer (HGSC) subtype alone account for ~90% of ovarian cancer associated
deaths [16]. Patients who harbor hereditary mutations in BRCA1, BRCA2, BRIP1, PALB2, RAD51C and
RAD51D have been shown to exhibit a higher risk of developing HGSC [16]. It is interesting to note
the recent paradigm shift related to the cell of origin for the predominant subtype of ovarian cancer i.e.,
HGSC. Using a Dicer-Pten double-knockout mouse model, Matzuk’s team was able to trace ovarian
cancers to fallopian tube mesenchyme and demonstrated that removal of fallopian tube, not ovaries,
led to prevention of HGSC [17]. Most recently, Velculescue et al. provide convincing evolutionary
evidence of the metastatic progression of HGSC in ovaries from precursor lesions in fallopian tube
tissue using laser captured microdissected tissues and whole-exome sequence analysis [18]. These and
other studies point toward a possible shared developmental origin for epithelial ovarian cancers.
In this current study, we utilized a multiplex PCR-based telomere fusion assay called TAR (telomere
associated repeat) fusion PCR to examine adjacent normal, benign, and malignant ovarian human
tissues. Our method allowed a quantitative analysis of the frequency of telomere fusions from human
solid tissues [11,12]. The major goal of this study is to determine the extent of telomere dysfunction
as reflected the telomere fusion accumulation in human ovarian tumor tissues. We also assessed
indicators of telomere dysfunction such as shortened telomere lengths and anaphase bridges, which
suggest onset of genomic instability and are frequently associated with telomere fusion-break-fusion
cycles. In addition, we evaluated telomere length, telomerase activity, and mRNA levels of the
reverse transcriptase protein subunit of the telomerase enzyme (hTERT). Telomere fusions were found
in significant quantities in ovarian tumor tissues, while limited telomere fusions were detected in
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“normal” adjacent tissues or benign ovarian human tissue samples. Furthermore, telomerase activity
was elevated in 100% of tumor tissues examined, but was not detectable in normal and benign tissues.
Overall, our data demonstrates widespread telomere dysfunction in ovarian cancer and suggests
that telomere dysfunction may occur at early stages of ovarian cancers. Continual cycles of telomere
dysfunction likely drives additional genomic instability, which may lead to metastatic transformation
in ovarian cancers and may play a pivotal role in the establishment of disease in these patients.
2. Materials and Methods
2.1. Ovarian Tissues
“Normal” tumor adjacent tissue, benign tumor tissue, and malignant tumor tissue (25–80 years
old; mean age 55 ± 16 years) were obtained from the IU Cancer Center Tissue Bank at the IU Simon
Cancer Center using an Indiana University School of Medicine Institutional Review Board-approved
protocol. Informed consent was obtained in writing from all participants involved. Immediately
following surgical removal, tissue specimens were placed in iced, sterile containers and transferred to
Pathology for diagnosis and processing. Each portion of deidentified tissue was given a unique barcode
for identification. Each tissue specimen contained approximately 100–250 mg of tissue. All tissue
samples were obtained by excisional biopsy and were examined histologically by pathologists at the
IU Simon Cancer Center for analysis. Additional information on tissue samples utilized in this study is
provided in Tables 1 and 2.
Table 1. Breakdown of patient samples received from IU Cancer Center Tissue Bank at the IU Simon
Cancer Center. hTERT mRNA, telomerase activity, telomere length, and telomere fusion information
from subsequent tests is included.
No. Age(Yr) Histologic Type
Tissue
Location
hTERT
mRNA
Expression
Telomerase
Activity
Telomere
Length (Kb)
Telomere
Fusion
N1 54 normal Ovary − − 7.21 −
N2 36 normal Ovary − − 7.77 +
N3 44 normal Ovary − − 7.36 −
N4 52 normal Ovary − − 6.12 −
N5 46 normal Ovary − − 7.80 −
N6 42 normal Ovary − − 8.26 −
N7 80 normal Uterusmyometrium − − 8.98 −
N8 58 normal Ovary − − 8.83 −
N9 55 normal Ovary − − 7.25 −
N10 48 normal Endometrium − − 7.90 −
N11 51 normal Endometrium − − 6.90 −
N12 67 normal Ovary − − 8.98 −
N13 50 normal Ovary − − 7.59 −
N14 47 normal Uterusmyometrium − − 7.21 −
B1 25
benign,
fibrothecoma,
Brenner’s tumor
Ovary − − 5.82 −
B2 26 benign Ovary − − 6.26 −
B3 41 benign Ovary − − 7.32 −
B4 30 benign Ovary − − 7.90 −
B5 82 benign Ovary − − 6.83 −
B6 65 benign Ovary − − 7.20 −
B7 35 benign Ovary − − 8.53 +
B8 62 benign Ovary − − 7.28 −
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Table 1. Cont.
No. Age(Yr) Histologic Type
Tissue
Location
hTERT
mRNA
Expression
Telomerase
Activity
Telomere
Length (Kb)
Telomere
Fusion
B9 79 benign Ovary − − 6.15 +
B10 69 benign Ovary − − 9.23 −
B11 39 benign Ovary − − 6.21 −
B12 45 benign Ovary − − 4.44 −
B13 60 benign Ovary − − 6.39 −
B14 51 benign Ovary − − 6.35 −
B15 66 benign Ovary − − 6.09 −
B16 81 benign Ovary − − 6.90 −
B17 60 benign Ovary − − 5.82 −
B18 48 benign Ovary − − 6.26 −
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Table 2. Ovarian tumor tissues.
No. Age(Yr) Histologic Type Grade
hTERT mRNA
Expression
Telomerase
Activity
Telomere
Length
Telomere
Fusion
OT1 42 papillary serous cystadenocarcinoma, nos II + + 4.80 −
OT2 75 papillary serous cystadenocarcinoma, nos III + + 4.34 +
OT3 78 papillary serous cystadenocarcinoma, nos - low malignant potential II + + 4.42 +
OT4 65 mixed papillary serous cystadenocarcinoma and endometriod carcinoma III + + 3.89 +
OT5 50 serous cystadenocarcinoma, nos II + + 3.64 +
OT6 80 serous cystadenocarcinoma, nos III + + 3.79 +
OT7 52 mixed carcinoma (endometriod and mucinous), nos I + + 6.50 +
OT8 56 carcinoma, nos, borderline serous tumor with intraepithelial carcinoma III + + 5.21 +
OT9 80 carcinoma, nos, 80% tumor, 20% necrosis III + + 5.22 +
OT10 77 carcinoma, nos I + + 6.83 −
OT11 58 carcinoma, nos high + − 6.16 −
OT12 65 carcinoma, nos high + + 4.60 +
OT13 57 adenocarcinoma, nos III + + 6.17 −
OT14 70 adenocarcinoma, nos high-grade + + 7.14 −
OT15 56 adenocarcinoma, nos II + + 5.45 −
OT16 46 adenocarcinoma, nos II + + 7.06 −
OT17 60 adenocarcinoma, nos IIIC + + 4.81 −
OT18 58 papillary adenocarcinoma, nos I + + 4.47 −
OT19 79 papillary carcinoma, nos IIIC + + 3.66 −
OT20 52 clear cell adenocarcinoma, nos III − + 5.51 −
OT21 44 clear cell adenocarcinoma, nos III + + 3.72 −
OT22 50 serous carcinoma III + + 4.42 −
OT23 48 serous adevocarcinoma III + + 4.30 +
OT24 56 poor differentiated adenocarcinoma III + + 4.57 −
OT25 60 Papillary serous adenocarcinoma III + + 6.79 −
OT26 70 Endometrioid III + + 4.63 +
OT27 65 Papillary serous adenocarcinoma III + + 5.27 −
OT28 64 Papillary serous carcinoma III + + 5.41 −
OT29 69 mucinous III + + 6.93 −
OT30 58 mixed with papillary serous carcinoma and clear cell III + + 5.92 +
OT31 74 Papillary serous adenocarcinoma III + + 6.60 +
OT32 60 serous cystadenocarcinoma, nos II + + 4.47 +
OT33 61 poor differentiated adenocarcinoma III + + 5.66 −
OT34 82 Papillary serous carcinoma III + + 5.40 +
OT35 64 Papillary serous carcinoma II + + 4.80 +
OT36 53 serous carcinoma III + + 4.97 −
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2.2. DNA/RNA/Protein Isolation
DNA, RNA, and protein were isolated from ovarian tissue samples using the AllPrep
DNA/RNA/Protein Mini Kit (Qiagen, Hilden, Germany, Catalog #80004) according to provided
protocol. RNA isolated with this protocol was used to synthesize cDNA using the QuantiTect Reverse
Transcription Kit (Qiagen, Catalog #205311) according to provided protocol. Resulting DNA, RNA,
and protein concentrations in each sample were assessed using a Nanodrop 2000 spectrophotometer
(Thermo Fisher Scientific, Waltham, MA, USA).
2.3. TAR Fusion PCR
Two-step touchdown PCR was performed in an Applied BioSystems Veriti Thermal Cycler in
a 20 µL reaction mixture using 50 ng of DNA, 8 different primers, 10 mM 7-deaza-dGTP (Roche
Diagnostics), and Advantage GC Genomic LA Polymerase Mix (Clontech). PCR cycling conditions
included 1 denaturation cycle of 3 minutes at 94 ◦C, 10 cycles each of 30 seconds at 94 ◦C and 5 minutes
of a temperature diminishing from 72 ◦C to 68 ◦C by 0.4◦C with each successive cycle (the “touchdown”),
and 20 additional cycles of 30 seconds at 94 ◦C and 5 minutes at 68 ◦C. Primer Mix A contained eight
primers that anneal within TAR1 regions (with the exception of Xp and 17p): 1p, 2p, 5p, 7q, 9p, 11q,
12q, 15q, 16p, 17p, 18p, Xp, and Xq. Primer Mix B contained eight primers that anneal within TAR1
regions (with the exception of Xp and 17p): 1q, 2p, 4p, 4q, 5p, 7q, 10q, 12q, 17p, 18p, 19q, 21q, and
Xp. Primer sequences are listed in publication by Tanaka et al. [11]. TAR fusion PCR products were
then resolved on a 0.8% agarose gel, and Southern blot analysis was performed using a 32P-labeled
[TTAGGG]4 probe. Normal male DNA and BJ foreskin fibroblast cell DNA were used as negative
controls. BJ cells expressing the human papillomavirus type 16 E6/E7 oncoproteins (BJ E6/E7) DNA
and ductal carcinoma in situ (DCIS) breast tumor tissue DNA, both previously identified to exhibit
numerous telomere fusions were used as positive controls [19].
To calculate the total number of possible telomere fusion combinations, the general equation C(n,2)
+ n was used, where n is the number of unique chromosomal ends. This equation can be simplified to
n(n+1)/2. In human somatic cells with 46 possible unique chromosome ends, there are (46 × 47)/2 = 1081
possible end-to-end fusion combinations. Each primer mix covers 13 chromosome ends (n = 13), so
each primer mix can detect (13 × 14)/2 = 91 possible fusion combinations. Primer Mix A and Primer
Mix B share 7 primers for a total number of (7 × 8)/2 = 28 shared fusion combinations. Thus, the total
number of possible fusion combinations detected by both primer mixes is 91 + 91 − 28 = 154, for a
total percentage of coverage of 154/1081 = 14.2%. [11,20].
2.4. Telomere Length
Telomere length of ovarian tissue DNA was assessed using the Cawthon method [21]. Six 20 µL
reactions per tissue sample were assayed by qPCR in a Roche LightCycler 480 under the following
cycling conditions: 1 cycle of 10 minutes at 94 ◦C, 2 cycles of 10 seconds at 94 ◦C followed by
15 seconds at 49 ◦C, and 35 cycles of 10 seconds at 94 ◦C followed by 15 seconds at 62 ◦C followed by
30 seconds at 74 ◦C. Reaction mixtures with no template DNA (nuclease-free water only) were used as
negative controls.
2.5. Telomerase Activity
Telomerase activity in ovarian tissue lysates was measured by Telomeric Repeat Amplification
Protocol (TRAP) using the TRAPeze Telomerase Detection Kit (Millipore). Tissue were lysed with ice
cold 1x CHAPS lysis buffer, and one 50µL reaction per tissue sample was prepared using 0.5 µg of
protein extract, 10× TRAP Precision Buffer, dNTPs, primers, and 2 U of Taq DNA polymerase. Reaction
mixtures were subjected to the following PCR cycling conditions in an Eppendorf MasterCycler
Gradient: 1 cycle of 30 minutes at 30 ◦C, 1 cycle of 5 minutes at 95 ◦C, and 33 cycles of 30 seconds at
95 ◦C followed by 30 seconds at 52 ◦C followed by 30 seconds at 72 ◦C. To view telomerase-generated
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bands, PCR products were electrophoresed on a 12.5% polyacrylamide gel and stained with SYBR
Green (Roche Diagnostics). A heat-inactivated sample was used as a negative control, and a positive
control was provided with the kit.
2.6. hTERT Expression
Three reactions per tissue sample were assayed with the TaqMan system as described by Bièche
et al. [22] using a Roche LightCycler 480 and probes from the Roche Universal Probe Library (Roche
Diagnostics). Reaction mixtures with no template DNA (nuclease-free water only) and DNA from
telomerase-negative BJ cells were used as negative controls. DNA from HeLa cells was used as a
positive control, and hTERT expression in tissue samples was quantitated by comparison with hTERT
expression in the control HeLa cells.
2.7. Analysis of Anaphase Bridges
All formalin fixed-paraffin embedded tissues were received from the Indiana University Simon
Cancer Center Tissue Bank with Indiana University School of Medicine Institutional Review Board
approval. Tissue blocks were sectioned and stained with Haematoxylin and Eosin (H&E) and scored
microscopically (Leica DN5000B) for anaphase bridges in ovarian tumor tissue and corresponding
adjacent, histologically normal ovarian tissue [23,24]. An anaphase bridge was defined as a continuous
chromatin link between two separated chromosome masses at anaphase [25].
3. Results
We used our multiplex TAR fusion PCR assay to investigate the presence of telomere end-to-end
fusions in ovarian tissue specimen obtained from oophorectomy surgeries [11]. Following patient
consent, we collected 54 tissues including 18 benign and 36 malignant tissues. We also collected
14 contralateral tumor-free ovarian tissues. The collection of primers used in our assay has been
calculated to cover approximately 14% of all possible chromosomal end-to-end combinations
(see Materials and Methods section for detailed calculation information) due to the currently limited
availability of known telomere adjacent sequences that can be used for primer synthesis. Despite
this limitation in coverage of potential chromosomal end-to-end fusions, 16 out of 36 tumor samples
(44%) displayed clear fusion bands on Southern blot analysis, while adjacent normal and benign
samples showed limited telomere fusions (1 out of 14 normal adjacent tissues, 7%; 2 out of 18 benign
tissues, 11%) (Figure 1). These results highlight a distinct difference between non-malignant and
malignant tissue, and illustrate the predominance of telomere dysfunction as a shared characteristic of
ovarian malignancies.
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BJ cells expressing the human papillomavirus type 16 E6/E7 oncoproteins (BJ E6/E7) DNA and ductal 
carcinoma in situ (DCIS) DNA are used as positive controls. (B) The percentage of fusion-positive 
samples. Standard t-test analysis is shown. (C) Frequency of telomere fusions where each dot 
represented one individual with the number of telomere fusion Southern bands per 500ng genomic 
DNA from five TAR-Fusion PCRs. 
Telomere fusion junction sequence analysis revealed that the majority of telomere fusion 
junctions from ovarian tumor tissue contained subtelomeric DNA to subtelomeric DNA fusion 
junctions lacking telomeric DNA (58.6%; Figure 2A and 2B). Additionally, we found fusion junctions 
with relatively short telomeric DNA tracts from one chromosome fused to subtelomeric DNA regions 
from another distinct chromosome end (17.2%; Figure 2A and B), and short telomeric DNA to short 
telomeric DNA fusion junctions containing telomeric DNA likely from both chromosomes involved 
in the fusion events (24.1%; Figure 2A and B). Previously, we reported that fusion junctions within 
DCIS (grade 3) breast tumor tissue did not contain significant levels of microhomology at telomere 
fusions junctions [11]. The telomere fusion junctions examined within this ovarian tumor tissue study 
also revealed no significant levels of microhomology. 
Figure 1. Telomere fusions in the ovarian tissue samples. (A) Southern blot analysis using 32P-labled
[TTAGGG]4 probe. Five representative samples are shown for normal and benign, and 12 for tumor
tissue samples. Normal male DNA and BJ foreskin fibroblast cells are used as negative controls, while
BJ cells expressing the human papillomavirus type 16 E6/E7 oncoproteins (BJ E6/E7) DNA and ductal
carcinoma in situ (DCIS) DNA are used as positive controls. (B) The percentage of fusion-positive
samples. Standard t-test analysis is shown. (C) Frequency of telomere fusions where each dot
represented one individual with the number of telomere fusion Southern bands per 500ng genomic
DNA from five TAR-Fusion PCRs.
Telomere fusion junction sequence analysis revealed that the majority of telomere fusion junctions
from ovarian tumor tissue contained subtelomeric DNA to subtelomeric DNA fusion junctions lacking
telomeric DNA (58.6%; Figure 2A,B). Additionally, we found fusion junctions with relatively short
telomeric DNA tracts from one chromosome fused to subtelomeric DNA regions from another distinct
chromosome end (17.2%; Figure 2A,B), and short telomeric DNA to short telomeric DNA fusion
junctions containing telomeric DNA likely from both chromosomes involved in the fusion events
(24.1%; Figure 2A,B). Previously, we reported that fusion junctions within DCIS (grade 3) breast
tumor tissue did not contain significant levels of microhomology at telomere fusions junctions [11].
The telomere fusion junctions examined within this ovarian tumor tissue study also revealed no
significant levels of microhomology.
To further elucidate the dynamics of telomere maintenance in ovarian tissue, we next assessed
activity of the telomerase enzyme in each tissue sample using the telomeric repeat amplification
protocol (TRAP). Minimal to no appreciable telomerase activity was detected in adjacent normal and
benign samples, while notable elevation in telomerase activity was observed in 100% of tumor tissue
samples (Figure 3A and Table 1). Although this data was not quantitatively analyzed, it nevertheless
provides qualitative empirical evidence that a clear difference exists between non-tumor and tumor
ovarian tissue with regard to telomerase activity – a distinction that correlates with hTERT mRNA
expression levels in these samples as described below.
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Analysis of hTERT expression in each tissue sample found that neither the adjacent normal nor the 
benign tissue samples contained detectable levels of hTERT mRNA, while 19 of the 20 tumor samples 
displayed substantial hTERT expression (P = 0.035 between adjacent normal and tumor tissue; Figure 
Figure 2. Telomere length and fusion analysis. (A) Each tumor tissue sample was evaluated for telomere
length using qPCR. Each sample’s fusion type, categorization of fused chromosomes, and telomeric
DNA (bp) length is shown. (B) Breakdown of the types of telomere fusion found in the above samples.
mRNA expression of the aforementioned catalytic subunit of the telomerase enzyme, known
as hTERT, was measured in ovarian tissue by comparison with hTERT expression in control HeLa
cells. Analysis of hTERT expression in each tissue sample found that neither the adjacent normal
nor the benign tissue samples contained detectable levels of hTERT mRNA, while 19 of the 20 tumor
samples displayed substantial hTERT expression (P = 0.035 between adjacent normal and tumor tissue;
Figure 3B). Tumor tissue samples on average exhibited 49% of the hTERT expression of HeLa cells.
These results correlate strongly with the qualitative telomerase activity data obtained via the TRAP
assay. This suggests that the telomerase enzyme is actively synthesized in malignant ovarian tissue
and may play a significant role in telomere maintenance and cancer progression in these malignancies.
Since degradation of the telomere has been implicated in the initiation of telomere fusions
and subsequent breakage-fusion-bridge cycles, we also examined telomere length in our samples.
Telomere length was determined by qPCR and showed significant differences between tissue categories
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(Figure 3C,D). Mean telomere length for adjacent normal ovarian tissue was 7.85 kb (SE = 0.40),
benign tissue showed shorter telomeres at a mean length of 6.65 kb (SE = 0.12), and ovarian tumor
tissue samples showed even shorter telomeres at a mean length of 5.2 kb (SE = 0.15). Our results
suggest that progressive shortening of telomere length may contribute to telomere dysfunction in
ovarian carcinoma.
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Figure 3. hTERT, telomerase, and telomere length profiles of ovarian carcinoma tissue samples.
(A) Representative samples with telomerase activity in ovarian carcinoma. Fresh lysates of HeLa cells
were used as positive control for telomerase activity while heat treated HeLa cells with inactivated
telomerase serve as negative control. (B) Representative samples of hTERT expression levels in ovarian
carcinoma quantified. HeLa and BJ cells were used as positive and negative controls respectively.
(C) Representative Southern Blot of telomere length comparing normal, benign and tumor ovarian tissue.
(D) Quantified mean telomere length (kb) of normal, benign and tumor tissue samples (mean ± SE).
Standard t-test analysis is shown.
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We performed anaphase bridge analysis for ovarian tumor lesions to determine if additional
markers of genomic instability associated with telomere dysfunction were specifically detected in
ovarian lesion epithelial lesions as opposed to other tissue cell types. We examined sectioned tissues
from ovarian tumor lesions along with corresponding adjacent normal tissue from each lesion from
10 patients (Figure 4). We found that epithelial cells, but not other cell types, from ovarian tumor
lesions contained significant levels of anaphase bridges (Figure 4B). Corresponding normal adjacent
tissue from each ovarian lesion did not contain detectable levels of anaphase bridges (Figure 4A). These
results highlight the presence of additional marker for genomic instability (anaphase bridges) within
ovarian tumor tissue and suggest that epithelial cells may be the cell type of origin of telomere fusions.
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Figure 4. Anaphase bridge analysis in ovarian carcinoma. Tissue sections are stained with Hematoxylin
and Eosin (H&E). (A) and (B) are representative adjacent tissue and ovarian carcinoma tissue sections,
respectively. (C) The percent of anaphase bridges was calculated from the total anapases within each
ovarian carcinoma.
4. Discussion
We determined the extent of telomere dysfunction in human epithelial ovarian carcinoma in order
to evaluate whether this form of genomic instability plays a role in ovarian carcin genesis. Specifically,
we s arch d for evidence of telomere fusio s, wh ch re known to initiate bre kage-fusion-bridge
cycles th t can subsequently lead to ext nsiv genomic damage and instability, a prime suspect in th
development of certain cancer types [26]. Our findings support the hypothesis th t telomere fusions are
a prevalent ev nt during ovarian malig ancies, as 44% of the tumor tissue samples (given the limitation
of curr nt as ay as previously discussed in the results section a d below) assayed were positive for
telomere fusio s, whereas adjacent normal and benign tissues showed s gnificant lower levels of
telomere fusion. Our data is consistent with the genomic evolution model of solid tumors that is also
applicable to ovarian cancer [27]. Based on our results an the ev lution model, we speculate that he
relatively preserved genomic integrity in benign issue is the characteristic of the majo ity of prevalent
subc ones in these tissue sampl s, but a rare, albeit undetectable tu or subclone(s) with compromised
telomere integrity and aneuploidy, may expand in number and become increasingly detectable during
the malignant growth phase. As mentioned previously, the current limitations of our assay enable
us to detect only 14% of the possible chromosome end-to-end telomere fusion combinations. In spite
of this limitation, 44% of the tumor tissues assayed exhibited the presence of telomere fusions. Such
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a high prevalence of telomere fusions, derived from such a limited number of possible associations
with the current assay indicates that telomere fusions are frequent and widespread events in ovarian
carcinoma. Furthermore, this strongly suggests that a substantial fraction of the 56% of tissues that
did not exhibit detectable levels of telomere fusions would likely be positive for telomere fusions if
the remaining 86% of possible end-to-end chromosome fusion combinations could be detected in
the telomere fusion assay with increased coverage. Although it is possible that certain chromosome
ends may fuse more frequently than others, our previous study of breast cancer [11], along with this
current report, in which fusion junctions were sequenced, showed no particular prevalence of any
specific types of fusion between specific chromosomes. In addition, since the primer combinations
utilized in this assay were determined randomly, solely by virtue of unique terminal chromosomal
DNA sequences at the time of assay development, it is unlikely that certain telomere ends are more
likely to form fusions in the current 14% coverage range. Therefore, in light of the apparently stochastic
nature of fusions indicated by our previous work, it is improbable that fusions in ovarian cancer would
occur at significantly different frequencies. This data provides striking evidence for the pervasive and
potentially ubiquitous nature of telomere dysfunction in ovarian cancer, a unifying characteristic of a
profoundly heterogeneous disease that may act as a driving force in tumorigenesis.
Previously published data on ovarian cancer has shown that ovarian tumors exhibit significantly
shorter telomeres than normal tissues [28–30]. Other research, however, has indicated that changes in
telomere length can include both shortening and elongation and that telomere length has no significant
relationship to the stage of disease. [31,32]. One difficulty in assessing the importance of telomere
length is the fact that assays performed on frozen tissue samples only provide a snapshot of telomere
dynamics at one specific moment in time. Investigators are left to discern whether or not the conditions
observed in telomere maintenance have reached a stable, static state or if they are moving toward
one extreme or the other. Captured in a brief moment in time, it is difficult to know if the telomere
lengths measured in an assay represent a constant, stable length that has remained at that level for an
indefinite period of time, if they are in the process of shortening with successive cell divisions, or if
telomere-elongation pathways such as activated telomerase or alternative lengthening of telomeres
(ALT) [33] may be lengthening them and rescuing them from genomic crisis. Each individual tumor
may differ from others in this regard, and intra-tumoral heterogeneity may even cause differences in
telomere dynamics within the same tumor. Malignant cells in a tumor tissue may feature critically short
telomeres, while non-malignant neighboring cells may have telomeres of a more normal length. This
potentially broad variety of telomere length in the cells of a single tumor may skew the mean telomere
length measurements for these tissues and prevent an accurate comparison of tissue types. Given these
potential complications with determining telomere length in tumor tissue samples, here we found
significant shorting of telomere lengths in ovarian tumor tissue cells compared to adjacent normal
ovarian tissue cells and benign ovarian tissue cells. Therefore, progressive shortening of telomere
length appears to likely contribute to telomere dysfunction in ovarian carcinoma.
hTERT expression and telomerase activity illuminate yet another facet of ovarian cancer telomere
dynamics. While the RNA component of the telomerase enzyme (known as hTR) is expressed
constitutively in both adjacent normal and malignant tissues [34,35], expression of the catalytic subunit
hTERT is highly regulated in human cells. Believed to be the rate-limiting factor in telomerase activity,
ectopic expression of hTERT in cells lacking active telomerase has been shown to restore enzymatic
activity, highlighting the critical role of hTERT in telomerase function [36,37]. Telomerase activation
wields the potential to rescue critically short telomeres from a state of crisis, thereby extending a cell’s
replicative life span, but it has also been suggested that telomerase aids in maintaining the telomere’s
protective protein cap and may even signal to the cell to continue dividing, even when the telomeres are
not concurrently lengthening [38]. hTERT expression and telomerase activity therefore clearly illustrate
an important element of telomere dynamics. In this study, ovarian tumor tissue exhibited substantial
hTERT expression and telomerase activity, while adjacent normal and benign ovarian tissues showed
no hTERT mRNA or corresponding telomerase activity. This marked distinction clearly underscores
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the import of telomerase in cancer, although its precise role may not yet be fully understood [39,40].
Whether the enzyme is rescuing critically short telomeres from a point of crisis, maintaining telomeric
integrity, or performing some other signaling function that prompts the cell to continue dividing,
the presence and activation of telomerase in cancer cannot be denied. The striking difference between
telomerase expression and activity in tumor tissue and their non-malignant counterparts unequivocally
highlights a pivotal role telomerase appears to play in the development and progression of ovarian
carcinoma. Dysfunctional telomere structure, via telomere shortening and other modes, resulting in
telomere fusions, leading to genomic instability via breakage-fusion-bridge cycles, is likely a driving
factor in the subsequent mis-regulation of telomerase activity in tumor cells.
In conclusion, the results presented here provide direct evidence of telomere dysfunction in
human ovarian carcinoma. This data strongly suggests that telomere dysfunction occurs at a high
frequently in ovarian cancer and likely plays a pivotal role in driving ovarian tumor development
through breakage-fusion-bridge cycles leading to genomic instability. Deregulation of telomerase
activity, likely due to this and other modes of genomic instability, are then required to maintain
chromosome ends to promote malignant transformation of these damaged cells. Augmenting our
knowledge regarding when and how telomere dysfunction occurs in a variety of human tissue types
will likely enable us to elucidate more specific processes and common pathway in cancer development.
This knowledge will be a key component in improved clinical methods of detection, treatment, and
prevention of this and other diseases associated with telomere dysfunction.
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